Stockscreener 앱 받기
3.37
13.14%
-0.51
시간 외 거래:
3.60
0.23
+6.82%
전일 마감가:
$3.88
열려 있는:
$4.04
하루 거래량:
12.76M
Relative Volume:
15.28
시가총액:
$117.35M
수익:
$50.23M
순이익/손실:
$-36.40M
주가수익비율:
-2.9823
EPS:
-1.13
순현금흐름:
$-27.10M
1주 성능:
+46.52%
1개월 성능:
+27.17%
6개월 성능:
-7.16%
1년 성능:
-51.58%
1일 변동 폭
$3.30
$4.4799
1주일 범위
$1.92
$4.4799
52주 변동 폭
$1.81
$7.56
908 디바이시스 Stock (MASS) Company Profile
명칭
908 Devices Inc
전화
978-729-4478
주소
645 SUMMER STREET, BOSTON
MASS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MASS
908 Devices Inc
|
3.37 | 117.35M | 50.23M | -36.40M | -27.10M | -1.13 |
|
ABT
Abbott Laboratories
|
137.71 | 238.83B | 41.95B | 13.40B | 6.35B | 7.65 |
|
BSX
Boston Scientific Corp
|
104.71 | 154.53B | 16.75B | 1.85B | 2.37B | 1.25 |
|
SYK
Stryker Corp
|
395.69 | 150.99B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
94.06 | 120.61B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
72.85 | 42.83B | 5.72B | 4.17B | 259.90M | 6.97 |
908 디바이시스 Stock (MASS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-11-13 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2023-02-07 | 개시 | Stephens | Overweight |
| 2021-10-15 | 재개 | Cowen | Outperform |
| 2021-01-12 | 개시 | Cowen | Outperform |
| 2021-01-12 | 개시 | SVB Leerink | Outperform |
| 2021-01-12 | 개시 | Stifel | Buy |
| 2021-01-12 | 개시 | William Blair | Outperform |
모두보기
908 디바이시스 주식(MASS)의 최신 뉴스
Repligen lays down $70m to buy analytics tech from 908 Devices - BioProcess Insider
Stifel maintains Buy on 908 Devices, target steady at $6 - Investing.com
Stifel maintains Buy on 908 Devices, target steady at $6 By Investing.com - Investing.com UK
Repligen Purchases Bioprocessing Analytics Portfolio from 908 Devices - Genetic Engineering & Biotechnology News
908 Devices Inc.'s (NASDAQ:MASS) 55% Jump Shows Its Popularity With Investors - Simply Wall St
908 Devices Inc (MASS) Q4 2024 Earnings Call Highlights: Strong Revenue Growth Amid Strategic ... - Yahoo Finance
908 Devices Inc. Reports Strategic Transformation and Growth - TipRanks
908 Devices stock surges on strategic transformation and growth outlook By Investing.com - Investing.com South Africa
908 Devices stock surges on strategic transformation and growth outlook - Investing.com India
Repligen Corporation acquired the assets related to bioprocessing analytics portfolio of 908 Devices Inc. for $56 million. - Marketscreener.com
908 Devices jumps as Repligen buys bioprocessing analytics portfolio - MSN
Earnings call transcript: 908 Devices Q4 2024 revenue up 31%, stock surges - Investing.com India
908 Devices Strategic Shift: Desktop Sale To Repligen Optimizes Future Growth - Benzinga
Strategic Divestment and Focus on Growth Propel 908 Devices to a Buy Rating - TipRanks
908 Devices earnings missed by $0.33, revenue fell short of estimates - Investing.com
908 Devices reports Q4 EPS (56c), consensus (35c) - TipRanks
908 Devices Inc. reports results for the quarter ended December 31Earnings Summary - TradingView
Repligen Corporation acquired Bioprocessing Analytics Portfolio from 908 Devices Inc. for $70 million. - Marketscreener.com
Repligen’s Strategic Acquisition of 908 Devices’ Bioprocessing Assets Boosts Buy Rating - TipRanks
MASSive Gains for 908 Devices: Is This Stock Turning Around? - RagingBull
908 Devices Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2024 - Marketscreener.com
Investor presentation (03/04/2025 00: 00 - Marketscreener.com
908 Devices Inc. (MASS) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
Repligen Acquires 908 Devices’ Bioprocess Analytics Portfolio - Contract Pharma
908 DEVICES Earnings Results: $MASS Reports Quarterly Earnings - Nasdaq
908 Devices stock jumps on Repligen deal (RGEN:NASDAQ) - Seeking Alpha
Repligen acquires 908 Devices’ desktop bioprocessing tech - Investing.com India
908 Devices stock soars on divestiture and revenue growth - Investing.com
Repligen Buys 908 Devices' Desktop Portfolio for $70 Million -March 04, 2025 at 08:07 am EST - Marketscreener.com
908 Devices Announces Strategic Transformation and Reports Fourth Quarter and Full Year 2024 Financial Results - TradingView
908 Devices sells desktop assets, sees revenue growth - Investing.com
BRIEF-908 Devices Q4 EPS USD -0.56 - TradingView
Repligen purchases 908 Devices’ bioprocessng analytics portfolio for $70M - TipRanks
How Will 908 Devices' $70M Portfolio Sale to Repligen Reshape Its Business Strategy? - StockTitan
908 Devices to Participate in Upcoming Investor Conferences - 01Net
Want to Hear From 908 Devices Leadership? Two Major Healthcare Conferences Coming Up - StockTitan
908 Devices to Report Fourth Quarter and Full Year 2024 Financial Results on March 4, 2025 - Business Wire
908 Devices (MASS) Projected to Post Quarterly Earnings on Tuesday - Defense World
ARK Investment Management LLC Has $6.14 Million Stock Position in 908 Devices Inc. (NASDAQ:MASS) - MarketBeat
908 Devices' chief product officer sells $18,190 in stock - MSN
908 Devices (MASS) to Release Quarterly Earnings on Tuesday - MarketBeat
908 devices CEO Kevin J. Knopp sells $37,109 in stock - MSN
10 Biotech Companies in Germany to Know - Built In
908 Devices (NASDAQ:MASS) Given Sell (E+) Rating at Weiss Ratings - Defense World
908 Devices Inc. (NASDAQ:MASS) Shares Sold by Sumitomo Mitsui Trust Group Inc. - Defense World
Insider Selling: 908 Devices Inc. (NASDAQ:MASS) Insider Sells 9,672 Shares of Stock - MarketBeat
908 Devices' (MASS) Sell (E+) Rating Reaffirmed at Weiss Ratings - MarketBeat
February 2025 US Penny Stocks To Watch - Simply Wall St
908 Devices Inc. (NASDAQ:MASS) CFO Sells $23,952.24 in Stock - MarketBeat
908 Devices’ (MASS) Sell (E+) Rating Reaffirmed at Weiss Ratings - Defense World
908 디바이시스 (MASS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.73%
0.56%
자본화:
|
볼륨(24시간):